CoChat

Effectiveness of Naltrexone in a Community Treatment Program

Killeen, Therese K., Brady, Kathleen T., Gold, Paul B., Simpson, Kit N., Faldowski, Richard A., Tyson, Clare, Anton, Raymond F. · 2004 · Alcoholism: Clinical and Experimental Research
Cited by 60

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Objective: In several large, well‐designed, randomized, double‐blind studies, the opiate antagonist naltrexone demonstrated efficacy in the treatment of alcohol dependence. Specifically, when combined with certain psychosocial therapies, naltrexone reduces the number of drinking days, heavy drinking, and time to relapse to alcohol use in alcohol‐dependent individuals. Whether this efficacy can be generalized to individuals who have alcohol use disorders and present for treatment at front‐line community treatment programs has not been well established. Methods: A total of 145 patients who presented for treatment at a rural community substance abuse treatment center were randomized to receive naltrexone 50 mg daily plus usual program treatment (n= 54), placebo plus usual treatment (n= 43), or usual treatment alone (n= 48) for 12 week. A total of 133 participants had at least one follow‐up visit. Primary outcome measures included percent days drinking, average drinks per drinking day, average drinks per day, heavy drinking days (four or more for women and six or more for men), and time to first heavy drinking day. Secondary measures included changes in serum biological markers (alkaline phosphatase, alanine transaminase, aspartate transaminase, and γ‐glutamyltransferase), craving, and psychosocial functioning. Results: In the intention‐to‐treat analysis, there were no between‐group differences for any of the primary drinking outcomes at 12 weeks. In post hoc exploratory analyses, the entire sample of participants was divided into two new groups: (1) people who drank during the 2 weeks before the start of medication (entry drinkers) and (2) people who did not drink during this interval (entry abstainers). Entry abstainers were at an advantage at study entry in that they were significantly more likely to have an inpatient hospitalization immediately before entry into outpatient treatment. Mixed‐model analysis of variance revealed a main effect for entry group at the 12‐week treatment endpoint on the primary outcome measures of percent days drinking, average drinks per drinking day, average drinks per day, heavy drinking days, and time to first heavy drinking day. Participants in any of the randomized groups who were entry abstainers had significantly better improvement on all of the primary outcome measures. The abstainer groups that were randomized to placebo and usual treatment had significantly better outcomes than the entry drinkers in those perspective groups. However, for the naltrexone‐treated group, entry drinkers and entry abstainers had similar improvement in drinking‐related outcomes. Conclusions: These data suggest that naltrexone may offer particular benefit to patients who continue to drink during the early stages of the trial as compared with those who have achieved abstinence before treatment entry.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.alc.0000145688.30448.2c

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 60

Metadata

Authors
Killeen, T. K., Brady, K. T., Gold, P. B., Simpson, K. N., Faldowski, R. A., Tyson, C., & Anton, R. F.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2004-11
Volume
28
Issue
11
Pages
1710-1717
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2074728576
Cited by
60
References
4
FWCI
3.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of Naltrexone in a Community Treatment Program. https://app.cochat.ai/papers/10.1097/01.alc.0000145688.30448.2c
The paper
Killeen, T. K., Brady, K. T., Gold, P. B., Simpson, K. N., Faldowski, R. A., Tyson, C., & Anton, R. F. (2004). Effectiveness of Naltrexone in a Community Treatment Program. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1097/01.alc.0000145688.30448.2c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.